BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 6415561)

  • 1. [Therapeutic results in advanced ovarian cancer].
    Kleinmanns G; Dauer W; Knief JJ; Westerhausen M
    Onkologie; 1983 Aug; 6(4):206-9. PubMed ID: 6415561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO).
    Gadducci A; Brunetti I; Bruzzone M; Carnino F; Chiara S; Conte PF; Fioretti P; Foglia G; Ragni N
    Eur J Gynaecol Oncol; 1992; 13(1 Suppl):36-9. PubMed ID: 1511712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
    Cohen CJ; Bruckner HW; Goldberg JD; Holland JF
    Clin Obstet Gynaecol; 1983 Aug; 10(2):307-24. PubMed ID: 6413114
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of 2 different forms of chemotherapy on remission in patients with advanced ovarian cancer].
    Krommer K; Keller G; Csaba I; Garadnay B; Göcze P
    Zentralbl Gynakol; 1990; 112(17):1105-10. PubMed ID: 2264421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The study of cyclic maintenance chemotherapy with cisplatin, adriamycin, and cyclophosphamide (cyclic PAC chemotherapy) in patients with advanced ovarian cancer].
    Kobayashi H; Hayata T; Terao T; Kawashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1936-42. PubMed ID: 2592816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-look procedures in ovarian cancer patients receiving six vs. nine courses of platinum, adriamycin, cytoxan (PAC) chemotherapy: the SCPMG experience 1982-1985.
    Watring W; Semrad N; Alaverdian V; Latino F; Pretorius G
    Gynecol Oncol; 1989 Feb; 32(2):245-7. PubMed ID: 2910787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
    J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Kooyman CD; van Lindert AC; Hamerlynck JV; van Lent M; van Houwelingen JC
    Lancet; 1984 Sep; 2(8403):594-600. PubMed ID: 6147640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intermittent administration of the combination chemotherapy with cis-platin, adriamycin and cyclophosphamide (cyclic-PAC chemotherapy) for the ovarian cancers].
    Inoue M; Nakanishi K; Nakazawa A; Ogawa H; Shimizu H; Saitoh J; Tanaka Y; Ueda G; Tanizawa O
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):347-52. PubMed ID: 2358719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
    Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
    J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chemotherapy of advanced ovarian cancer. Göttingen-Hannover studies].
    Kühnle H; Hilfrich J
    Onkologie; 1985 Dec; 8(6):374-82. PubMed ID: 3912694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin-containing versus cisplatin-free adjuvant chemotherapy in ovarian carcinoma. Results after second-look laparotomy.
    Schneider J; Martin M; Erasun F; Matia JC; Rodriguez-Escudero FJ
    Oncology; 1990; 47(2):109-11. PubMed ID: 2314822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
    Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
    J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of cisplatin alone and in combination within the scope of primary therapy of ovarian cancer. Results of a prospective multicenter study].
    Richter P; Krafft W; Müller U; Brückmann D; Homann S; König EM; Lotze P; Morack G; Neubert S; Nöschel H
    Zentralbl Gynakol; 1990; 112(7):421-9. PubMed ID: 1695049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of advanced ovarian cancer].
    de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J
    Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.